Kazia Therapeutics Limited ADR [NASDAQ: KZIA] closed the trading session at $0.31. The company report on March 21, 2024 at 8:52 AM that Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases. Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology
Kazia Therapeutics Limited ADR [NASDAQ: KZIA] loss -8.89% or -0.03 points to close at $0.25 with a heavy trading volume of 3310143 shares. The company report on March 21, 2024 at 8:52 AM that Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare
Kazia Therapeutics Limited ADR [NASDAQ: KZIA] price plunged by -20.61 percent to reach at -$0.08. The company report on February 21, 2024 at 7:30 AM that Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint. Paxalisib plus Radiotherapy Data Shows Promise for
Kazia Therapeutics Limited ADR [NASDAQ: KZIA] gained 5.57% or 0.02 points to close at $0.37 with a heavy trading volume of 2599926 shares. The company report on January 18, 2024 at 7:30 AM that KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS. Kazia Therapeutics Limited
© 2024, Powered by Smart TechOne
